Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(4):275-278
DOI: 10.5428/pcar20180410
Analysis of two cases of drug-induced malignant arrhythmia
1. ZHENG XiaoXiao1(1.Department of Pharmacy, Xuzhou First People’s Hospital, Jiangsu Xuzhou 221002, China xiaoxiao-0912@163.com)
2. XU ShengQiu1(1.Department of Pharmacy, Xuzhou First People’s Hospital, Jiangsu Xuzhou 221002, China )
3. CHE ZaiQian2(2.Emergency Intensive Care Unit, Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China chezai qian@163.com)
4. HE Juan3(3.Department of Pharmacy, Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China hejuanwin@126.com)
ABSTRACT  Objective: To investigate clinical characteristics and risk factors of drug-induced malignant arrhythmia. Methods: The drugs used and risk factors in the two cases of drug-induced malignant arrhythmia were analyzed. Results: The occurrence of arrhythmia in the two cases was associated with the use of drugs, such as amiodarone, sotalol, moxifloxacin, azithromycin and fluconazole. There were multiple risk factors for arrhythmia in the two cases, including the female sex, senior age,background diseases or hepatorenal insufficiency, and combined use of drugs that prolong QT interval. After withdrawal of these drugs, electrocardiogram returned to normal. Conclusion: Drugs that could prolong the QT interval must be used with caution in patients with risk factors of drug-induced malignant arrhythmias.
Welcome to PCAR! You are the number 64 reader of this article!
Please cite this article as:
ZHENG XiaoXiao1,XU ShengQiu1,CHE ZaiQian2,HE Juan3,. Analysis of two cases of drug-induced malignant arrhythmia[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(4): 275-278.
References:
1. Kennelly C, Esaian D. Drug-induced cardiovascular adverse events in the intensive care unit[J]. Crit Care Nurs Q,2013,36(4):323-334.
2. Nielsen D G, Nielsen J C, Trolle C, et al. Prolonged QT interval and cardiac arrest after a single dose of amiodarone in a woman with Turner’s syndrome[J]. Clin Case Rep,2017,5(2):154-158.
3. ZHOU Zheng. The efficacy and safety of amiodarone and sotalol in the treatment of arrhythmia[J]. China Pract Med,2016,11(10):168-169. In Chinese.
4. Mehlhorn A J, Brown D A. Safety concerns with fluoroquinolones[J]. Ann Pharmacother,2007,41(11):1859-1866.
5. TANG LiHua. Analysis of QT interval prolongation and ventricular arrhythmia induced by moxifloxacin[J]. Cent South Pharm,2017,15(2):251-253. In Chinese.
6. Hancox J C, Hasnain M, Vieweg W V R, et al. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports[J]. Ther Adv Infect Dis,2013,1(5):155-165.
7. CHOU HsuWen, WANG JiunLing, CHANG ChiaHsiun, et al. Examining the risks of cardiac arrhythmia and mortality among new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a nationwide study[J]. Clin Infect Dis,2015,60(4):566-577.
8. Freeman B D, Dixon D J, Coopersmith C M, et al. Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients[J]. Pharmacoepidemiol Drug Saf,2008,17(10):971-981.
9. Barnes B J, Hollands J M. Drug-induced arrhythmias[J]. Crit Care Med,2010,38(6 Suppl):S188-S197.
10. Muzyk A J, Rayfield A, Revollo J Y, et al. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol[J]. Drug Saf,2012,35(7):547-553.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口